We are live on ! Find out more
TCRT icon

Alaunos Therapeutics

140 hedge funds and large institutions have $409M invested in Alaunos Therapeutics in 2019 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 53 increasing their positions, 25 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

180% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 10

112% more repeat investments, than reductions

Existing positions increased: 53 | Existing positions reduced: 25

70% more capital invested

Capital invested by funds: $241M → $409M (+$168M)

13% more funds holding

Funds holding: 124140 (+16)

0.03% more ownership

Funds ownership: 0.26%0.29% (+0.03%)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

37% less call options, than puts

Call options by funds: $8.42M | Put options by funds: $13.3M

Holders
140
Holders Change
+16
Holders Change %
+12.9%
% of All Funds
3.04%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
28
Increased
53
Reduced
25
Closed
10
Calls
$8.42M
Puts
$13.3M
Net Calls
-$4.89M
Net Calls Change
-$5.61M
Name Holding Trade Value Shares
Change
Change in
Stake
AllianceBernstein
26
AllianceBernstein
Tennessee
$1.36M -$18.6K -27 -2%
OWIM
27
Old West Investment Management
California
$1.3M -$1.38K -2 -0.1%
California Public Employees Retirement System
28
California Public Employees Retirement System
California
$1.29M +$146K +212 +17%
Bank of America
29
Bank of America
North Carolina
$1.28M -$1.28M -1,863 -56%
SIG
30
Sargent Investment Group
Maryland
$1.26M +$77.7K +113 +8%
Renaissance Technologies
31
Renaissance Technologies
New York
$1.2M +$946K +1,375 New
RhumbLine Advisers
32
RhumbLine Advisers
Massachusetts
$1.19M +$141K +205 +18%
Rafferty Asset Management
33
Rafferty Asset Management
New York
$1.18M -$29.6K -43 -3%
State of Wisconsin Investment Board
34
State of Wisconsin Investment Board
Wisconsin
$1.05M +$18.6K +27 +2%
New York State Common Retirement Fund
35
New York State Common Retirement Fund
New York
$958K +$174K +253 +30%
Goldman Sachs
36
Goldman Sachs
New York
$953K +$143K +208 +24%
6CM
37
683 Capital Management
New York
$875K -$229K -333 -25%
Citadel Advisors
38
Citadel Advisors
Florida
$868K +$683K +993 New
HighTower Advisors
39
HighTower Advisors
Illinois
$827K -$58.5K -85 -8%
Wells Fargo
40
Wells Fargo
California
$779K +$101K +147 +20%
UC
41
Unio Capital
New Jersey
$706K +$550K +800 New
LTFS
42
Ladenburg Thalmann Financial Services
Florida
$643K -$19.3K -28 -4%
AIG
43
American International Group
New York
$595K +$83.2K +121 +22%
CS
44
Credit Suisse
Switzerland
$591K +$51.6K +75 +12%
Manulife (Manufacturers Life Insurance)
45
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$586K +$51.6K +75 +13%
CSS
46
Cubist Systematic Strategies
Connecticut
$564K +$444K +645 New
Wolverine Trading
47
Wolverine Trading
Illinois
$557K +$105K +152 +31%
PAG
48
Private Advisor Group
New Jersey
$554K +$105K +153 +32%
T. Rowe Price Associates
49
T. Rowe Price Associates
Maryland
$540K +$3.44K +5 +0.8%
Janney Montgomery Scott
50
Janney Montgomery Scott
Pennsylvania
$530K +$41.3K +60 +11%

TCRT Hedge Fund Activity: Q2 2019 in Review

140 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Alaunos Therapeutics (TCRT) for Q2 2019, worth a combined $409M — up 70% from $241M a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new TCRT positions and 10 closed out — a net gain of 18 holders — while 53 added to existing stakes and 25 trimmed.

The largest buyer was BlackRock, adding an estimated $10.5M. The largest seller was Bank of America, cutting an estimated $1.28M.

  • 140 institutional investors held Alaunos Therapeutics (TCRT) as of Q2 2019, up from 124 in Q1 2019.
  • Funds reported $409M of Alaunos Therapeutics stock for Q2 2019, up 70% quarter-over-quarter.
  • 28 funds opened new Alaunos Therapeutics positions in Q2 2019 and 10 closed out, a net change of +18 holders.
  • The largest Alaunos Therapeutics buyer in Q2 2019 was BlackRock, an estimated $10.5M added.
  • The largest Alaunos Therapeutics seller in Q2 2019 was Bank of America, an estimated $1.28M sold.

Based on aggregated 13F filings for Q2 2019.